These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33884719)

  • 21. [Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].
    Descazeaud A; Barry Delongchamps N; Cornu JN; Azzouzi AR; Buchon D; Benchikh A; Coloby P; Dumonceau O; Fourmarier M; Haillot O; Lebdai S; Mathieu R; Misrai V; Saussine C; de La Taille A; Robert G;
    Prog Urol; 2015 Jun; 25(7):404-12. PubMed ID: 25841758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
    Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
    BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment.
    Roehrborn CG; Egan KB; Miner MM; Ni X; Wong DG; Rosen RC
    BJU Int; 2016 Jul; 118(1):153-60. PubMed ID: 26765325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
    Silva J; Silva CM; Cruz F
    Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications.
    Seftel A; Rosen R; Kuritzky L
    Int J Impot Res; 2007; 19(4):386-92. PubMed ID: 17377613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary care physician versus urologist: how does their medical management of LUTS associated with BPH differ?
    Miner MM
    Curr Urol Rep; 2009 Jul; 10(4):254-60. PubMed ID: 19570485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
    Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
    BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia.
    Russo A; Capogrosso P; La Croce G; Ventimiglia E; Boeri L; Briganti A; Damiano R; Montorsi F; Salonia A
    Expert Opin Drug Saf; 2016 Dec; 15(12):1661-1670. PubMed ID: 27232207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics.
    Roehrborn CG; Nuckolls JG; Wei JT; Steers W;
    BJU Int; 2007 Oct; 100(4):813-9. PubMed ID: 17822462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Observational database serenoa repens (DOSSER): overview, analysis and results. A multicentric SIUrO (Italian Society of Oncological Urology) project.
    Bertaccini A; Giampaoli M; Cividini R; Gattoni GL; Sanseverino R; Realfonso T; Napodano G; Fandella A; Guidoni E; Prezioso D; Galasso R; Cicalese C; Scattoni V; Armenio A; Conti G; Corinti M; Spasciani R; Liguori G; Lampropoulou N; Martorana G
    Arch Ital Urol Androl; 2012 Sep; 84(3):117-22. PubMed ID: 23210402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
    Vela-Navarrete R; Alcaraz A; Rodríguez-Antolín A; Miñana López B; Fernández-Gómez JM; Angulo JC; Castro Díaz D; Romero-Otero J; Brenes FJ; Carballido J; Molero García JM; Fernández-Pro Ledesma A; Cózar Olmos JM; Manasanch Dalmau J; Subirana Cachinero I; Herdman M; Ficarra V
    BJU Int; 2018 Dec; 122(6):1049-1065. PubMed ID: 29694707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tadalafil - a therapeutic option in the management of BPH-LUTS.
    Carson CC; Rosenberg M; Kissel J; Wong DG
    Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia.
    Lepor H
    Urol Clin North Am; 2016 Aug; 43(3):311-23. PubMed ID: 27476124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
    Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effectiveness of Omnic and Omnic Ocas in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia (multi-center observing program)].
    Shalekenov BU; Kuandykov YA; Shalekenov SB
    Urologiia; 2017 Oct; (5):42-47. PubMed ID: 29135141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
    Kim SW; Park NC; Lee SW; Yang DY; Park JK; Moon DG; Yang SK; Lee SW; Moon KH; Ahn TY; Kim SW; Park K; Min KS; Ryu JK; Son H; Jung J; Hyun JS
    J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Lower urinary tract symptoms secondary to benign prostatic hyperplasia in 2017: update from the 32nd annual congress of European association of urology].
    Ergakov DV; Martov AG
    Urologiia; 2017 Jul; (3 (supplement)):36-44. PubMed ID: 28845926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence-based guidelines for the management of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary.
    Spatafora S; Conti G; Perachino M; Casarico A; Mazzi G; Pappagallo GL;
    Curr Med Res Opin; 2007 Jul; 23(7):1715-32. PubMed ID: 17588302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Singh DV; Mete UK; Mandal AK; Singh SK
    J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacological treatment of benign prostatic hyperplasia].
    Oelke M; Martinelli E
    Urologe A; 2016 Jan; 55(1):81-94; quiz 95-6. PubMed ID: 26676726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.